Department of Veterinary Clinical Sciences, University of Copenhagen, Dyrlaegevej 16, Frederiksberg, 1870, Denmark.
Evidensia Södra Djursjukhuset Kungens Kurva, Månskärsvägen 13, 141 75 Kungens, Kurva, Sweden.
Acta Vet Scand. 2023 Oct 19;65(1):46. doi: 10.1186/s13028-023-00709-7.
Meningoencephalitis of unknown origin is a common cause of severe neurological disease in dogs. The term covers a heterogeneous group of noninfectious inflammatory diseases, with immune dysregulation widely accepted as the underlying disease mechanism. Current treatment consists of immunosuppression, with corticosteroids being the mainstay of virtually all treatment regimens. However, side effects of corticosteroids can be severe, and might be the cause of death in some patients. This retrospective, multi-centric study aimed at describing a population of Scandinavian dogs with meningoencephalitis of unknown origin in regards to reported side effects and cause of death, and to highlight possible differences in survival, when comparing corticosteroid monotherapy with other treatment regimens.
Within the 5-year study period, 63 dogs were included. Of these, 35 (49.3%) died or were euthanized during the study period. Median survival time from time of diagnosis based on Kaplan-Meier curves for the overall population was 714 days (equivalent to around 25 months, range 0-1678 days). There was no statistically significant difference (P = 0.31) in survival between dogs treated with corticosteroid monotherapy (n = 26, median survival time 716 days, equivalent to around 25 months, range 5-911 days), dogs receiving a combination of corticosteroids and ciclosporin (n = 15, median survival time 916 days, equivalent to around 31 months, range 35-1678 days), and dogs receiving corticosteroids combined with either cytosine arabinoside, leflunomide, or a combination of 2 or more add-on drugs (n = 13, median survival time 1186 days, equivalent to around 40 months, range 121-1640 days). Side effects were registered for 47/63 dogs. Polyphagia (n = 37/47), polyuria/polydipsia (n = 37/47), diarrhea (n = 29/47) and lethargy (n = 28/47) were most frequently reported. The most common cause for euthanasia was relapse (n = 15/35, 42.9%), followed by insufficient or lack of treatment response (n = 9, 25.7%). Side effects were the direct cause of euthanasia in 2/35 dogs (5.7%).
A large proportion of dogs in the overall population were euthanized due to relapse, emphasizing a need for treatment regimens aimed at specifically preventing relapse for an improved long-term survival. Side effects in dogs receiving corticosteroid monotherapy were rarely a direct cause of death, but were reported for all dogs. No statistically significant difference in survival was found when corticosteroid monotherapy was compared to other treatment regimens.
不明原因的脑膜脑炎是犬严重神经疾病的常见病因。该术语涵盖了一组非传染性炎症性疾病,免疫失调被广泛认为是潜在的疾病机制。目前的治疗方法包括免疫抑制,皮质类固醇是几乎所有治疗方案的主要药物。然而,皮质类固醇的副作用可能很严重,在某些患者中可能是导致死亡的原因。本回顾性、多中心研究旨在描述一组来自斯堪的纳维亚的患有不明原因脑膜脑炎的犬,报告其副作用和死亡原因,并强调在比较皮质类固醇单药治疗与其他治疗方案时,生存方面可能存在的差异。
在 5 年的研究期间,共纳入 63 只犬。其中,35 只(49.3%)在研究期间死亡或被安乐死。基于总体人群的 Kaplan-Meier 曲线,从诊断时间到死亡时间的中位生存时间为 714 天(相当于约 25 个月,范围 0-1678 天)。接受皮质类固醇单药治疗(n=26,中位生存时间 716 天,相当于约 25 个月,范围 5-911 天)、皮质类固醇联合环孢素治疗(n=15,中位生存时间 916 天,相当于约 31 个月,范围 35-1678 天)和皮质类固醇联合阿糖胞苷、来氟米特或 2 种以上附加药物治疗(n=13,中位生存时间 1186 天,相当于约 40 个月,范围 121-1640 天)的犬之间,生存时间无统计学差异(P=0.31)。皮质类固醇单药治疗(n=47/63)、皮质类固醇联合环孢素治疗(n=15/63)和皮质类固醇联合阿糖胞苷、来氟米特或 2 种以上附加药物治疗(n=13/63)的犬均出现副作用。最常报告的副作用有:多食(n=37/47)、多尿/多饮(n=37/47)、腹泻(n=29/47)和嗜睡(n=28/47)。安乐死的最常见原因是复发(n=15/35,42.9%),其次是治疗反应不足或缺乏(n=9,25.7%)。有 2/35 只(5.7%)犬的副作用是直接导致安乐死的原因。
总体人群中很大一部分犬因复发而被安乐死,这强调了需要制定专门针对预防复发的治疗方案,以提高长期生存。接受皮质类固醇单药治疗的犬的副作用很少直接导致死亡,但所有犬都有报告。皮质类固醇单药治疗与其他治疗方案相比,生存时间无统计学差异。